JP2020520382A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520382A5
JP2020520382A5 JP2020513491A JP2020513491A JP2020520382A5 JP 2020520382 A5 JP2020520382 A5 JP 2020520382A5 JP 2020513491 A JP2020513491 A JP 2020513491A JP 2020513491 A JP2020513491 A JP 2020513491A JP 2020520382 A5 JP2020520382 A5 JP 2020520382A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520382A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032559 external-priority patent/WO2018209346A1/en
Publication of JP2020520382A publication Critical patent/JP2020520382A/ja
Publication of JP2020520382A5 publication Critical patent/JP2020520382A5/ja
Priority to JP2022195529A priority Critical patent/JP2023016969A/ja
Pending legal-status Critical Current

Links

JP2020513491A 2017-05-12 2018-05-14 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 Pending JP2020520382A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022195529A JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505558P 2017-05-12 2017-05-12
US62/505,558 2017-05-12
PCT/US2018/032559 WO2018209346A1 (en) 2017-05-12 2018-05-14 Use of anti-b7h3 antibodies for treating cancer in the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022195529A Division JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Publications (2)

Publication Number Publication Date
JP2020520382A JP2020520382A (ja) 2020-07-09
JP2020520382A5 true JP2020520382A5 (enExample) 2021-07-26

Family

ID=64102794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513491A Pending JP2020520382A (ja) 2017-05-12 2018-05-14 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用
JP2022195529A Pending JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022195529A Pending JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Country Status (11)

Country Link
US (2) US20200197546A1 (enExample)
EP (1) EP3635012A4 (enExample)
JP (2) JP2020520382A (enExample)
KR (1) KR20200008580A (enExample)
CN (1) CN110799542A (enExample)
AU (1) AU2018265888A1 (enExample)
BR (1) BR112019023776A2 (enExample)
CA (1) CA3062335A1 (enExample)
EA (1) EA201992683A1 (enExample)
RU (1) RU2019140833A (enExample)
WO (1) WO2018209346A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113853220A (zh) * 2019-03-11 2021-12-28 生物相容英国有限公司 用于中枢神经系统肿瘤治疗的放射性微球
EP4022313A1 (en) 2019-08-30 2022-07-06 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
WO2021190586A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN117024590A (zh) * 2020-04-22 2023-11-10 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
EP4138931A1 (en) 2020-04-24 2023-03-01 Y-Mabs Therapeutics, Inc. B7h3 antibodies with chelators
CN112961241B (zh) * 2020-06-30 2022-04-22 广州百暨基因科技有限公司 抗b7h3抗体及其应用
WO2022167052A1 (en) * 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
KR20230145038A (ko) 2021-02-09 2023-10-17 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 생물활성 물질 접합체, 이의 제조방법 및 이의 용도
US20240199750A1 (en) 2021-03-26 2024-06-20 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
KR20240019297A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
US20240392007A1 (en) * 2021-09-27 2024-11-28 Shenghe (China) Biopharmaceutical Co., Ltd. Heterodimeric protein and application thereof
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
CN119212733A (zh) 2022-05-18 2024-12-27 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024008039A1 (zh) * 2022-07-08 2024-01-11 盛禾(中国)生物制药有限公司 一种异源二聚体融合蛋白及其应用
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112017003582B1 (pt) * 2014-08-27 2024-01-09 Memorial Sloan Kettering Cancer Center Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico
WO2016106004A1 (en) * 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2020520382A5 (enExample)
RU2019140833A (ru) Применение антител против в7н3 для лечения злокачественных опухолей в центральной нервной системе
AU2017264955B2 (en) Combination of anti-PD-1 antibodies and radiation to treat cancer
Milenic et al. α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2
Sharkey et al. Cancer radioimmunotherapy
JP2023016969A5 (enExample)
JP2020512281A5 (enExample)
JP7274646B2 (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
US20160101199A1 (en) Method for upregulating antigen expression
Pohlman et al. Review of clinical radioimmunotherapy
JP2023165952A (ja) α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法
US20220143228A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
Lindén et al. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma
Skarbnik et al. Radioimmunotherapy in mantle cell lymphoma
US20250281654A1 (en) Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents
US20230248855A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
Hanaoka et al. Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody
Almqvist et al. Biodistribution of 211At-labeled humanized monoclonal antibody A33
JP2023550462A (ja) 固形がんの治療のためのｈｅｒ３放射免疫治療薬
JP2008540429A (ja) 癌の治療における併用療法
Cona et al. Continuing pursuit for ideal systemic anticancer radiotherapeutics
Mattes et al. Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons
Rathmann Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry
Mitra et al. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas
US20190192701A1 (en) Method for tumor-targeting treatment and diagnosis, conjugates used for the same, and preparation method thereof